Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics(TM), a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

We currently have a robust clinical-stage product pipeline and multiple preclinical product candidates. Our most advanced product candidates are in development for major depressive disorder and resistant hypertension, attention deficit/hyperactivity disorder, Alzheimer’s disease  and cognitive dysfunction in schizophrenia.

Targacept is located in Winston-Salem, North Carolina.

On May 26, 2009, The Scientist, magazine of the life sciences, announced the winners of its 7th annual "Best Places to Work in Industry" survey and Targacept was among the award winners...more.....   Targacept has several product candidates in clinical development. View our pipeline to learn more. Watch the animation to find out how our drugs work in the nervous system.

May 11, 2009 Targacept Reports First Quarter 2009 Financial Results May 11, 2009 Targacept Announces Positive Top-Line Results from Phase II Study of AZD3480 in Adult ADHD April 23, 2009 Targacept Initiates Phase 2 Study of TC-5214 in Patients with Resistant Hypertension March 11, 2009 Targacept Provides Update on TC-6499 and Pain Program in GlaxoSmithKline Alliance